<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01726413</url>
  </required_header>
  <id_info>
    <org_study_id>GRC 17536-203</org_study_id>
    <secondary_id>2012-002320-33</secondary_id>
    <nct_id>NCT01726413</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Study the Effects GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients).</brief_title>
  <official_title>A Phase II, 4-Week Randomised, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Pharmaceuticals Ltd. India</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glenmark Pharmaceuticals S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Glenmark Pharmaceuticals Ltd. India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic peripheral neuropathy (DPN) represents a diffuse symmetric and length-dependent
      injury to peripheral nerves that has major implications on quality of life (QOL), morbidity,
      and costs from a public health perspective. Painful diabetic neuropathy affects approximately
      16% of patients with diabetes. Pharmacological agents used in the management of painful DPN
      mainly include tricyclic antidepressants, selective serotonin and norepinephrine reuptake
      inhibitors, opioid, and anti epileptic drugs. The available treatment options do not give
      total relief, are not effective in all patients, and only about one-third of patients may
      achieve more than 50% pain relief. Hence newer therapies are required for the treatment of
      DPN. The primary outcome measures will be the change from baseline to end of treatment in the
      mean 24-hour average pain intensity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean 24-hour average pain intensity (API) score.</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean night-time API Score</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Global Impression of Change</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Painful Diabetic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Test Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GRC17356 for daily administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for daily administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRC 17356</intervention_name>
    <arm_group_label>Test Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients willing to provide voluntary written informed consent

          2. Male and female patients ≥18 yrs and ≤75 yrs

          3. Patients with diabetes mellitus with painful peripheral neuropathy for at least 6
             months

          4. A baseline 24-hour average daily pain intensity score ≥5

          5. Women must be of non child-bearing potential, defined as post menopausal or surgically
             sterile

        Exclusion Criteria:

          1. Other chronic pain conditions not associated with DPN, that may confound the
             assessment of neuropathic pain

          2. Other causes of neuropathy or lower extremity pain

          3. Complex regional pain syndrome or trigeminal neuralgia

          4. Lower extremity amputations other than toes

          5. Participation in another study with an investigational compound within the previous 90
             days prior to study medication administration, or concurrent participation in another
             clinical study

          6. Major depression.

          7. Presence or history of cancer within the past 5 years with the exception of adequately
             treated localized basal cell skin cancer or in situ uterine cervical cancer.

          8. Patients with clinically significant or uncontrolled hepatic, gastrointestinal,
             cardiovascular, respiratory, neurological (other than neuropathy), psychiatric,
             hematological, renal, or dermatological disease, or any other medical condition that
             according to Investigator's medical judgment: Could interfere with the accurate
             assessment of safety or efficacy, or, Could potentially affect a patient's safety or
             study outcome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Balamurugan Ramanathan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kovai Diabetes Speciality Centre and Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Vijay Viswanathan</last_name>
    <role>Principal Investigator</role>
    <affiliation>MV Hospital for Diabetes (P) Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Mallikarjun V Jali</last_name>
    <role>Principal Investigator</role>
    <affiliation>K.L.E.S Dr. Prabhakar Kore Hospital &amp; Medical research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Sunil M Jain</last_name>
    <role>Principal Investigator</role>
    <affiliation>TOTALL Diabetes Hormone Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Dinesh Dhanwal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maulana Azad Medical College &amp; Associate Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. S Srikanta</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jnana Sanjeevani Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Jayashri Shembalkar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Getwell Hospital and Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Peter Dewland</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON Manchester CPU</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Prof Thomas Forst</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Clinical Research and Development( IKFE-CRO GmbH BahnhofstraBe 8A)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Paramesh Shammana</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bangalore Clinisearch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Arthur Asirvatham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arthur Asirvathma Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Mohan Magdum</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jehangir Clinical development Centre Pvt Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Blanka Lubenova</last_name>
    <role>Principal Investigator</role>
    <affiliation>NeuroHelp s.r.o</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. David Dolezil</last_name>
    <role>Principal Investigator</role>
    <affiliation>DADO Medical s.r.o</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NeuroHelp s.r.o</name>
      <address>
        <city>Olomouc</city>
        <state>Prague</state>
        <zip>772 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DADO Medical s.r.o</name>
      <address>
        <city>Prague</city>
        <zip>12000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DADO Medical s.r.o</name>
      <address>
        <city>Ricany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical Research and Development( IKFE-CRO GmbH BahnhofstraBe 8A)</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bangalore Clinisearch</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560043</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K.L.E.S Dr. Prabhakar Kore Hospital &amp; Medical research Centre</name>
      <address>
        <city>Belgaum</city>
        <state>Karnataka</state>
        <zip>590010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jnana Sanjeevani Medical Centre</name>
      <address>
        <city>Bangalore</city>
        <state>Karntaka</state>
        <zip>560078</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TOTALL Diabetes Hormone Institute</name>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <zip>452010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jehangir Clinical development Centre Pvt Ltd</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Getwell Hospital and Research Centre</name>
      <address>
        <city>Nagpur</city>
        <state>Maharastra</state>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MV Hospital for Diabetes (P) Ltd</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600 013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kovai Diabetes Speciality Centre and Hospital</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641 009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur Asirvathma Hospital</name>
      <address>
        <city>Madhurai</city>
        <state>Tamil Nadu</state>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maulana Azad Medical College &amp; Associate Hospitals</name>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICON Manchester CPU</name>
      <address>
        <city>Manchester</city>
        <state>UK</state>
        <zip>M15 6SH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>India</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2012</study_first_submitted>
  <study_first_submitted_qc>November 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2012</study_first_posted>
  <last_update_submitted>October 1, 2014</last_update_submitted>
  <last_update_submitted_qc>October 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Pain</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

